Simpson Interventions Appoints Dr. Joseph Knight as CEO

June 12, 2024—Simpson Interventions, Inc., a medical technology company specializing in cardiovascular interventional devices, announced the appointment of Joseph Knight, PhD, to the role of Chief Executive Officer, effective May 1, 2024.

Dr. Knight succeeds Simpson Interventions’ Founder and previous CEO, John B. Simpson, MD, PhD.

Dr. Simpson will continue in his role as Chairman of the company’s Board of Directors, while additionally assuming the role of Chief Medical Officer. Dr. Simpson has been CEO since the founding of Simpson Interventions in 2019.

According to the company, Dr. Knight’s academic credentials include a PhD from the Swiss Federal Institute of Technology (ETH Zurich) in Zurich, Switzerland; an MBA in entrepreneurship and marketing from Duke University’s Fuqua School of Business in Durham, North Carolina; as well as bachelor’s and master’s degrees in engineering from the University of South Florida in Tampa, Florida. Additionally, he was a Fellow in Stanford University’s Biodesign Innovation Program in Stanford, California.

Most recently, Dr. Knight served as President and CEO of InnAVasc Medical until the company was acquired by W. L. Gore & Associates. Additionally, Dr. Knight has been part of the intellectual property development, business, and strategic planning for multiple early-stage ventures—including iRhythm Technologies, Lacuna Medial, Higgs Boson Health, and Medici Medical Technologies. Dr. Knight also served 5 years at Medtronic in various marketing, business development, and strategy roles.

“I’m thrilled to take the leadership mantle from Dr. Simpson, who has been a luminary in the field of cardiovascular medicine for generations,” commented Dr. Knight in the company’s press release. “Not only has Dr. Simpson grown Simpson Interventions into a company at the forefront of breakthroughs in interventional cardiology, but he’s also had the foresight to tackle the complex problems that have plagued the interventional cardiology community for decades. I’m honored to be able to follow in his footsteps and lead this great company forward.”

Dr. Simpson stated, “I’ve always believed my strength lies in taking a company from the ‘device-drawing-on-a-napkin’ phase to the ‘first-in-human’ phase. Now that we have reached this critical milestone, it is the perfect time to bring in a leader with the operational expertise to guide us through the next stages of growth.”

He continued, “Dr. Knight is exceptionally well-suited for this role, and I am thrilled to support him as Chief Medical Officer while we continue to revolutionize interventional cardiology together. His story is profoundly inspiring, and I am confident he will lead Simpson Interventions to new heights.”